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YMETHODS AND RESULTS Patients included in a multicenter registry at 5 centers in
Italy were systematically followed for major adverse cardiac events (MACE). Clinical
data were obtained for 92 patients (mean age 57.1 years, 74.0% males) with a total of
95 lesions treated with overlapping Absorb BVS. Fifty-seven (61.9%) patients under-
went scaffold implantation due to acute coronary syndrome. Diabetic patients were
17.3%. Multivessel disease was present in 63.0% of patients. Treated lesions were
type B1 (21.3%), type B2 (23.0%), and type C (55.7%). Mean length covered by over-
lapping BVS was 48.0 16 mm. The mean number of implanted Absorb BVS was 2.25
scaffolds per lesion and 2.63 scaffolds per patient. Angiographic and procedural
success occurred in all patients. At a median follow up of 10 months (interquartile
range, 5-14.75 months), cumulative occurrence of MACE was 4.34%. Adverse events
were: 1 possible late scaffold thrombosis (unexplained cardiac death occurring two
months after elective revascularization), 2 TLR due to BVS restenosis (documented
BVS recoil in 1 case), 1 TVR due to restenosis of drug eluting stent proximal to two
overlapped scaffolds.
CONCLUSIONS Our ﬁndings suggest that treatment of long lesions by means of
overlapped Absorb BVS appears to be safe at mid-term follow up.DRUG ELUTING STENTS
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BACKGROUND Percutaneous coronary intervention (PCI) of small vessels is associ-
ated with a high restenosis rate. Drug-eluting stents (DES) reduce restenosis in
coronary arteries, but the role of DES in small coronary vessels has not been well
deﬁned. In our systematic review, we aim to summarize all known angiographic and
clinical outcome of 2.25-mm DES, to highlight the need for speciﬁc outcome data in
this cohort.
METHODS A systematic literature search of 394 relevant citations from PubMed,
EMBASE, Web of Science and the Cochrane Central Register of Controlled
Trials yielded 8 eligible studies studying FDA approved 2.25-mm DES. Angiographic
and clinical outcome data were extracted and compared between each type
of DES. Subgroup analysis comparing clinical outcome between sirolimus-eluting
stents (SES) and paclitaxel-eluting stents (PES) was done using a random effects
model.
RESULTS Of the 8 studies included in the analysis, 6 were non-randomized and 2
were randomized against bare-metal stents (BMS). A total of 1,037 patients were
studied, with follow-up ranging from 1 month to 5 years. PES, SES and everolimus-
eluting stents (EES) were studied. Myocardial infarction at one year was highest in
PES vs. SES and EES: 4.2% vs. 3.4% and 1.5%. Target vessel revascularization at one
year was highest in PES vs. SES and EES: 13.8% vs. 5.7% and 8.8%. Death rate was
highest in PES at 4.2% vs. SES and EES (3.4% and 1.5%). Mean late lumen loss for PES,
SES, and EES was 0.280.11 mm, 0.150.11 mm, and 0.160.41 mm at 9 months to 1
year. Mean diameter stenosis for PES, SES and EES was 34.74.2%, 29.56.2%, and
20.922.5%. Mean binary stenosis for PES, SES and EES was 26.97.8%, 10.46.7%,
and 9.6% respectively. No 2.25 mm speciﬁc data was available for zotarolimus eluting
stents, which was reported in combination with larger stent sizes.
CONCLUSION Our composite data suggest that 2.25-mm SES and EES have superior
clinical and angiographic outcomes compared with 2.25-mm PES, which has been
shown to be superior to BMS in a randomized controlled study. Given the unique
theoretical challenges posed by small vessel PCI, the overall lack of randomized data
in this cohort needs to be addressed with future studies evaluating 2.25 mm stents in
next-generation DES.
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Republic ofBACKGROUND There have been limited data comparing efﬁcacy and safety of Bio-
limus-eluting Stents (BES, BiomatrixTM, Biosensors and NoboriTM, Terumo) with
Platinum Chromium Everolimus-eluting Stent (PtCr-EES, Promus ElementTM, Boston
Scientiﬁc) in a series of Asian population in real world clinical practice.
METHODS A total of 626 patients (pts) receiving BES or PtCr-EES were pooled from
our prospective percutaneous coronary intervention (PCI) registry from March 2008
to May 2013. To adjust potential confounders, a propensity score matched (PSM)
analysis was performed using the logistic regression model, and clinical outcomes
were compared between the two groups up to 12 months.
RESULTS After PSM analysis, 2 propensity-matched groups (149 pairs, n ¼ 298 pts, C-
statistic¼0.793) were generated and the baseline characteristics of the two groups
were balanced. Six to 9-month angiographic outcomes showed that the incidence of
binary in-stent restenosis was higher in the BES group than PtCr-EES (18.9% vs. 7.0%,
p¼0.034). This adverse angiographic outcomes were translated into worse 12-month
clinical outcomes; the incidence of target lesion revascularizations (TLR: HR; 3.879,
C.I; 1.06-14.2, p¼0.041) and TLR-MACE (HR; 3.465, C.I; 1.103-10.88, p¼0.033) BA9
were signiﬁcantly higher than PtCr-EES despite of similar incidence of mortality and
myocardial infarction.
CONCLUSIONS As compared with PtCr-EES, BES seem to be associated with higher
rate of TLR and TLR MACE up to 12-month in a series of Asian population in real world
clinical practice.
Table. Mid-term angiographic and 12-month Clinical Outcomes after propensity score matched analysisCRT-704
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BACKGROUND Clinical trials and meta-analyses demonstrate the low restenosis and
stent thrombosis risks of next generation drug eluting stents (DES). Co-evolution of
device, delivery technique, and drug-related factors all contribute, yet relative ad-
vantages are difﬁcult to surmise. On a background of optimized contemporary bare
metal stents (BMS), we asked if locally eluted drugs are still as useful or if simple
design changes might obviate need for drug, further enhancing performance, man-
ufacturability, and cost.
METHODS We hypothesized that thin, bare metal cobalt chromium or platinum
chromium stents modiﬁed with an ultra-hydrophilic surface (UHS) treatment could
reduce late intimal hyperplasia (IH) as with second-generation DES, yet maintain fast
healing akin to bare metal stents (BMS). To test this, commercially available, FDA-
approved DES and BMS were compared with UHS in A) porcine coronary models to
assess IH and late thrombosis; and B) a rabbit iliac model to assess early healing and
subacute thrombosis.
RESULTS In vitro tests demonstrated similar to faster endothelialization with
reduced platelet adhesion (97% reduction, p<0.001) compared with untreated BMS.
Hydrophilic treatment reduced IH in porcine coronary arteries relative to 3 corre-
sponding BMS and DES platforms (2-3-fold reduction in 30-day angiographic reste-
nosis; p<0.03). In contrast to early healing of UHS and BMS (porcine 30-day
endothelialization score uniformly 4.0 of 4.0; conﬁrmed in rabbit), DES trended to
delayed healing at one month (range 2.67 to 4.0 out of 4.0) that resolved by 3 months,
correlating with computed drug-receptor saturation. Elevation in thrombotic indices
correlated with reduced endothelialization (p<0.0002) and occurred most often with
DES, never with UHS (Poisson probability¼0.135).
CONCLUSION Ultra-hydrophilic surface treatment of contemporary stents conferred
excellent healing while moderating neointimal and thrombotic responses. With
